Version 1
: Received: 18 April 2020 / Approved: 19 April 2020 / Online: 19 April 2020 (13:15:27 CEST)
How to cite:
Fayssoil, A.; Davido, B.; Mustafic, H.; Dinh, A.; Mansencal, N. Heart in Patients Infected with 2019 Novel Coronavirus (COVID-19). Preprints2020, 2020040346 (doi: 10.20944/preprints202004.0346.v1).
Fayssoil, A.; Davido, B.; Mustafic, H.; Dinh, A.; Mansencal, N. Heart in Patients Infected with 2019 Novel Coronavirus (COVID-19). Preprints 2020, 2020040346 (doi: 10.20944/preprints202004.0346.v1).
Cite as:
Fayssoil, A.; Davido, B.; Mustafic, H.; Dinh, A.; Mansencal, N. Heart in Patients Infected with 2019 Novel Coronavirus (COVID-19). Preprints2020, 2020040346 (doi: 10.20944/preprints202004.0346.v1).
Fayssoil, A.; Davido, B.; Mustafic, H.; Dinh, A.; Mansencal, N. Heart in Patients Infected with 2019 Novel Coronavirus (COVID-19). Preprints 2020, 2020040346 (doi: 10.20944/preprints202004.0346.v1).
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging infectious disease with currently a pandemic state. Cardiac function can be involved, affecting prognosis, in addition with lung feature severity, particularly in patients with comorbidities. Since the renin angiotensin aldosterone (RAA) system may interact with SARS-Cov-2, researches are still ongoing to assess the prognostic value of RAA blockers in cardiology.
Keywords
coronavirus; heart; prognosis; COVID-19; ICU
Subject
MEDICINE & PHARMACOLOGY, Cardiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
